Form 4: Protalix BioTherapeutics Director Sells Shares

Protalix BioTherapeutics Director Amos Bar-Shalev sold 168 shares of common stock at $1.87 per share under a Rule 10b5-1 plan.

Summary

• Amos Bar-Shalev, a Director of Protalix BioTherapeutics, Inc. (PLX), reported the sale of common stock.
• The transaction involved the disposition of 168 shares of common stock.
• The shares were sold at a price of $1.87 per share.
• The transaction occurred on November 18, 2025.
• Following this transaction, Bar-Shalev directly owns 0 shares and indirectly owns 7,500 shares through a trust.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled.

Sentiment

Score: 5

Explanation: A director's sale of a very small number of shares, executed under a Rule 10b5-1 plan, is a routine insider transaction and does not typically indicate a strong positive or negative sentiment about the company's future prospects.

Positives

• The transaction was executed under a Rule 10b5-1 plan, which indicates a pre-scheduled sale not based on immediate, reactive decisions, enhancing transparency.

Negatives

• A director selling shares, even a small amount, could be perceived as a slight reduction in insider confidence, though the pre-planned nature mitigates this concern.

Future Outlook

This filing is an insider transaction report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• The sale of 168 shares of common stock by Amos Bar-Shalev, a Director of Protalix BioTherapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• The impact on shareholders is minimal due to the very small number of shares involved in the transaction.

Key Dates

Recommendation

The filing reports a routine, pre-planned sale of a very small number of shares by a director, which does not provide sufficient new information to alter an investment thesis. The transaction was executed under a Rule 10b5-1 plan, indicating it was not based on new material non-public information.

Keywords

Protalix BioTherapeutics, PLX, Amos Bar-Shalev, Form 4, Insider Trading, Stock Sale, Director Transaction, Rule 10b5-1, Common Stock